- Home
- JMSB vs SLN Comparison
JMSB vs SLN Comparison
Compare JMSB & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMSB | SLN |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.0M | 318.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JMSB | SLN |
|---|---|---|
| Price | $19.85 | $5.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $22.50 | ★ $39.67 |
| AVG Volume (30 Days) | 17.8K | ★ 329.0K |
| Earning Date | 01-30-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 18.50 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $59,274,000.00 | $25,830,000.00 |
| Revenue This Year | $19.50 | N/A |
| Revenue Next Year | $12.72 | N/A |
| P/E Ratio | $14.17 | ★ N/A |
| Revenue Growth | 11.69 | ★ 40.39 |
| 52 Week Low | $13.81 | $1.97 |
| 52 Week High | $21.58 | $7.78 |
Technical Indicators
Market Signals| Indicator | JMSB | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 30.95 |
| Support Level | $19.35 | $5.24 |
| Resistance Level | $20.35 | $6.11 |
| Average True Range (ATR) | 0.41 | 0.45 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 41.67 | 7.54 |
Price Performance
Historical ComparisonAbout JMSB John Marshall Bancorp Inc.
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.